Targeting CD276 (B7-H3) Positive Solid Tumors by 4SCAR-276

Inclusion Criteria

• •Patients with tumors have received standard first-line therapy and have been judged to be non-resectable, metastatic, progressive or recurrent.
• •The CD276 antigen status of the tumor is determined for eligibility. Positive expression is defined by antibody staining results based on immunohistochemistry or flow cytometry analysis.
• •Body weight greater than or equal to 10 kg.
• •Age: ≥1 year and ≤ 75 years of age at the time of enrollment.
• •Life expectancy: at least 8 weeks.
• •Prior Therapy: 1) There is no limit to the number of prior treatment regimens. Any grade 3 or 4 non-hematologic toxicity of any previous therapy must have resolved to grade 2 or less. 2) Must not have received hematopoietic growth factors for at least 1 week prior to mononuclear cells collection. 3) At least 7 days must have elapsed since the completion of therapy with a biologic agent, targeted agent, tyrosine kinase inhibitor or a metronomic nonmyelosuppressive regimen. 4) At least 4 weeks must have elapsed since prior therapy that included a monoclonal antibody. 5) At least 1 week since any radiation therapy at the time of study entry.
• •Karnofsky/jansky score of 60% or greater.
• •Cardiac function: Left ventricular ejection fraction greater than or equal to 40/55 percent .
• •Pulse Ox greater than or equal to 90% on room air.
• •Liver function: defined as alanine transaminase (ALT) \<3x upper limit of normal (ULN), aspartate aminotransferase (AST) \<3x ULN; serum bilirubin and alkaline phosphatase \<2x ULN.
• •Renal function: Patients must have serum creatinine less than 3 times upper limit of normal.
• •Marrow function: White blood cell count ≥1000/ul, Absolute neutrophil count ≥500/ul, Absolute lymphocyte count ≥500/ul, Platelet count ≥25,000/ul (not achieved by transfusion).
• •Patients with known bone marrow metastatic disease will be eligible for study as long as they meet hematologic function criteria, and the marrow disease not evaluable to have hematologic toxicity.
• •For all patients enrolled in this study, themselves or their parents or legal guardians must sign an informed consent and assent.